AI could spot severe asthma patients faster, study says
NCT ID NCT06389058
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses artificial intelligence and natural language processing to scan electronic health records and identify people with severe asthma. Researchers will compare the AI's findings to diagnoses made by doctors. The goal is to improve how severe asthma is detected and make it easier to find patients for future clinical trials. No new treatments are being tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify severe asthma patients more accurately and speed up enrollment in future clinical trials.
- What could go wrong
- This is an observational study using existing data, so it won't directly test any treatment. The AI models may not work perfectly across different healthcare systems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
San Diego State University
San Diego, California, 92182-1309, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Scientists probe why tezepelumab doesn't stop all asthma attacks
- Smart inhalers track Fasenra's asthma control over full dosing cycle